1. Markers of inflammation: data from the MOSAIC randomised trial of CPAP for minimally symptomatic OSA.
- Author
-
Stradling JR, Craig SE, Kohler M, Nicoll D, Ayers L, Nunn AJ, and Bratton DJ
- Subjects
- Biomarkers, Continuous Positive Airway Pressure, Humans, Inflammation etiology, Patient Compliance, Sleep Apnea, Obstructive therapy, C-Reactive Protein metabolism, Inflammation blood, Interleukin-10 blood, Interleukin-6 blood, Sleep Apnea, Obstructive complications, Tumor Necrosis Factor-alpha blood
- Abstract
Unlabelled: The Multi-centre Obstructive Sleep Apnoea Interventional Cardiovascular (MOSAIC) trial compared 6 months of CPAP therapy, versus no CPAP, in 391 patients with minimally symptomatic obstructive sleep apnoea (OSA). We now report some exploratory outcomes, markers of systemic inflammation (interleukin 6 (IL-6), IL-10, C reactive protein, tumour necrosis factor). We found no consistent changes (all p values >0.13)., Trial Registration Number: ISRCTN 34164388., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.)
- Published
- 2015
- Full Text
- View/download PDF